Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

OncLive Honors 15 Trailblazers With Giants of Cancer Care Program

May 28th 2019

Fifteen world-renowned leaders in hematology and oncology whose research has improved and extended the lives of millions of patients make up the 2019 class of Giants of Cancer Care® award winners.

NCCN Goes Global With Guidelines Tailored for Treatment Capabilities Abroad

May 20th 2019

The NCCN is working to develop modified guidelines for specific regions that offer less-costly and less–technologically intensive cancer treatment alternatives.

Sometimes the Weight of Tradition Is Heavier Than Gold-Standard Evidence in Oncology

May 18th 2019

Evidence generated from the randomized study design may be largely ignored by an individual or a community of physicians if the results or strategies being examined do not align with existing beliefs or bias, local practice and referral patterns, and other potentially highly relevant factors unrelated to the trial outcome.

Proton Therapy: A Path to Improved Outcomes and Quality of Life

May 17th 2019

Although development outlays with proton therapy have decreased, treatment costs remain higher than for conventional radiotherapy, fueling a debate about whether the benefits justify the costs.

Primary Care Physicians' Frustrations Mirror Those of Oncologists

May 12th 2019

In 2018, primary care physicians faced many of the same challenges as oncologists, according to the 90th Annual Physician Report from Medical Economics.

When the Quality of Evidence Just Doesn't Make the Grade in Cancer Care

May 10th 2019

The oncology clinical and research communities should demand that essential clinical trials and objectively valid evidence for efficacy and toxicity be obtained and reported before any regulatory agencies or national/international cancer societies support this strategy as a “standard of care” for cancer pain management.

Future Directions in Advanced Ovarian Cancer Management

April 29th 2019

Genetic Counseling for Patients With Ovarian Cancer

April 29th 2019

Sequencing Antiangiogenic Agents in Advanced Ovarian Cancer

April 29th 2019

Sequencing PARP Inhibitors in Advanced Ovarian Cancer

April 29th 2019

Prepping Patients With Advanced OC for PARP Inhibition

April 29th 2019

Management of PARP Inhibitor AEs in Ovarian Cancer

April 29th 2019

Impact of SOLO-1 on Advanced Ovarian Cancer Management

April 29th 2019

Advanced OC: Interpreting the Design and Results of SOLO-1

April 29th 2019

PARP Inhibitor Selection in Advanced OC

April 29th 2019

Recurrent Ovarian Cancer: PARP Inhibitor Maintenance Therapy

April 29th 2019

Advanced OC: Clinical Data Behind PARP Inhibition

April 29th 2019

Evolution of PARP Inhibitors in Advanced Ovarian Cancer

April 29th 2019

Comprehensive Review of Maintenance Therapy in Advanced OC

April 29th 2019

Frontline Therapy and Recurrence in Advanced Ovarian Cancer

April 29th 2019